[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) is advancing in oncology, as evidenced by its upcoming presentations at the 2025 ASCO Annual Meeting, which highlight its strong focus on cancer treatments. This coincided with a 2.66% rise in its share price last week. The company's progress included new data from several studies on its oncology portfolio, which could attract investor interest despite broader market declines driven by global trade tensions and tech sector losses. While the market overall fell...",
    "url": "https://finnhub.io/api/news?id=1af1bcf296bb99634a7a826a121f60a74391c37aa58fe180b5aa6e169bdc18fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748020867,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting",
      "id": 134685882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) is advancing in oncology, as evidenced by its upcoming presentations at the 2025 ASCO Annual Meeting, which highlight its strong focus on cancer treatments. This coincided with a 2.66% rise in its share price last week. The company's progress included new data from several studies on its oncology portfolio, which could attract investor interest despite broader market declines driven by global trade tensions and tech sector losses. While the market overall fell...",
      "url": "https://finnhub.io/api/news?id=1af1bcf296bb99634a7a826a121f60a74391c37aa58fe180b5aa6e169bdc18fd"
    }
  },
  {
    "ts": null,
    "headline": "EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort",
    "summary": "Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.",
    "url": "https://finnhub.io/api/news?id=b80fb798dae8544fb737701ecbac0f200d51112578b2775cd7f2b544a3fdf896",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748008620,
      "headline": "EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort",
      "id": 134685883,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.",
      "url": "https://finnhub.io/api/news?id=b80fb798dae8544fb737701ecbac0f200d51112578b2775cd7f2b544a3fdf896"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Should Watch Teva Despite Regional Risks",
    "summary": "Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=cf24b2a0bb360e2a3e02f53e94632fe654e0bd890ffdc8997680f5ed687da4e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748004723,
      "headline": "Why Investors Should Watch Teva Despite Regional Risks",
      "id": 134667049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1206782047/image_1206782047.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=cf24b2a0bb360e2a3e02f53e94632fe654e0bd890ffdc8997680f5ed687da4e5"
    }
  },
  {
    "ts": null,
    "headline": "With 81% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing",
    "summary": "Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...",
    "url": "https://finnhub.io/api/news?id=8275e4593ab634a5a904e7661cc45b42f937abb02290c6b086e5adc259312542",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747998023,
      "headline": "With 81% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing",
      "id": 134658794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...",
      "url": "https://finnhub.io/api/news?id=8275e4593ab634a5a904e7661cc45b42f937abb02290c6b086e5adc259312542"
    }
  },
  {
    "ts": null,
    "headline": "Avoid These Dividend Disasters Before It's Too Late",
    "summary": "Discover the risks threatening dividend stocks, from high interest rates to the AI revolution. Click for my look at several plays you may want to avoid.",
    "url": "https://finnhub.io/api/news?id=06f5132fd06871c86e03ce9e35c01302e51d62f73f23db7548979c66058e5bb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747988100,
      "headline": "Avoid These Dividend Disasters Before It's Too Late",
      "id": 134658093,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1485172638/image_1485172638.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover the risks threatening dividend stocks, from high interest rates to the AI revolution. Click for my look at several plays you may want to avoid.",
      "url": "https://finnhub.io/api/news?id=06f5132fd06871c86e03ce9e35c01302e51d62f73f23db7548979c66058e5bb5"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: to present oncology results",
    "summary": "Bristol Myers Squibb will present the latest data from its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology Annual Meeting, which will be held May 30-June 3 in...",
    "url": "https://finnhub.io/api/news?id=9ed5d143b3b5c4e67815fbda7575e43e05d7434be8751cf4c80f9bd9d86cab6c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747981283,
      "headline": "Bristol Myers: to present oncology results",
      "id": 134657140,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb will present the latest data from its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology Annual Meeting, which will be held May 30-June 3 in...",
      "url": "https://finnhub.io/api/news?id=9ed5d143b3b5c4e67815fbda7575e43e05d7434be8751cf4c80f9bd9d86cab6c"
    }
  }
]